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tive pulmonary diseases, asthma, coronary artery disease, diabetes, obesity, liver, 
or thyroid condition, cancer and stroke). Ordinary least square regression (OLS) 
and multinomial logistic regressions on low (< 1.0 mg/l), average (1-3 mg/l) and 
high (> 3 mg/l) were used to analyze the association between antidepressant use 
and CRP. Results: Antidepressant use was reported by 13% of the adults and the 
average CRP value for the sample was 4.85 mg/l (SE = 0.0113). 22% had low CRP, 
33% had average CRP and 45% had high CRP values. Average CRP values were not 
statistically different between antidepressant users and non-users. Other factors 
that were significantly associated with CRP were: perceived health status, smok-
ing and income. For example, adults with excellent perceived health status had 
significantly lower CRP values (p < 0.004) as compared to those with poor health 
status. ConClusions: In this population-based study, no statistically significant 
association between antidepressant use and inflammatory bio-markers were found 
in individuals with an inflammatory condition. Future research may need to focus 
on specific inflammatory conditions including depression.
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objeCtives: To estimate the annual aggregate expenditures of prescription phar-
maceuticals in the treatment of peripheral neuropathic pain in the United States 
over a seven year period. Methods: We utilized annually compiled data for the 
years 2005-2011 of the Medical Expenditure Panel Survey (MEPS), a publically avail-
able dataset to construct cross-sectional, representative estimates of medical 
expenses and utilization for the civilian, non-institutionalized US population. We 
identified cases using International Classification of Disease-Ninth Revision, Clinical 
Modification (ICD-9-CM) codes which denoted conditions prone to peripheral neu-
ropathy (diabetes mellitus and herpes zoster), or indicated peripheral neuropathy 
directly. These were associated with pharmacy records using Cerner Multum™ clas-
sifications for classes of medication commonly used for treating neuropathic pain. 
Prescriptions counts and costs were aggregated by year. Survey weighting, clustering 
and stratification variables were used to give unbiased national estimates of pre-
scription utilization and expenditures. All costs were inflated to 2011 dollars using 
the medical Consumer Price Index. Results: A total of 2782 survey respondents 
had at least one prescribed medicine associated with treatment of a neuropathic 
pain diagnosis, representing 2.9 million persons in 2005 and increasing to 3.9 million 
in 2011 (annual increase of 3.1%, p= 0.05). Both total prescriptions and total expendi-
tures peaked in 2008 ($1.1 billion(b) and 20.3 million (m) prescriptions, respectively), 
then declined through 2011. Narcotic analgesics and gabapentinoids were the drug 
classes with the largest mean annual expenditures ($305m and $211m) , followed by 
serotonin-noradrenalin reuptake inhibitors ($141m). Non-gabapentinoid anticon-
vulsants, tricyclic antidepressants, and topical analgesics had substantial declines 
in usage and expenditures from 2005 to 2011. Non-narcotic analgesics utilization 
and expenses, including NSAIDs and tramadol, remained largely stable during the 
study period. ConClusions: Prescription medications for peripheral neuropathic 
pain treatment experienced large swings in usage and expenditures from 2005-
2011, peaking in 2008 despite steady increases in the number of neuropathic pain 
medication users.
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objeCtives: This study examined patient age and gender as well as racial and 
geographic variations in the prevalence of cystic fibrosis (CF), a chronic lung 
disease common in children and young adults, in the U.S. Medicaid popula-
tion. Methods: A retrospective study was performed among the U.S. Medicaid 
fee-for-service (FFS) population from 2008 through 2009. CF patients were 
identified using International Classification of Disease, 9th Revision, Clinical 
Modification (ICD-9-CM) diagnosis code 277.0x. Patients with continuous Medicaid 
FFS enrollment in both 2008 and 2009 were included for analysis. Any managed 
care enrollment during the period was not permitted. CF prevalence was stratified 
by region, state, age, gender and race, for all patients and measured by number and 
percentage, in each category. Results: A total of 2,550 patients were diagnosed 
with CF among the Medicaid FFS population in 2008 and 2009. Prevalence was the 
highest (0.15%) for patients under age 40 years, followed by patients age 40 to 59 
(0.03%), and 60+ (0.01%). CF prevalence by race was also examined, with the follow-
ing results: White (0.06%), Hispanic (0.04%), Black (0.03%), Native American (0.02%) 
and Asian (0.02%). Male patients had a relatively higher prevalence compared to 
female patients (0.06% vs. 0.05%). Geographic variation was also analyzed, and 
the highest CF prevalence was observed in Minnesota (0.16%), followed by Ohio, 
Maryland, North Dakota (all at 0.11%) and West Virginia (0.09%). Patients residing 
in the Midwest had the highest prevalence rate (0.07%), compared to the Northeast 
(0.05%), South (0.04%) and West (0.03%). ConClusions: Statistical evidence shows 
that younger patients have a higher probability of being diagnosed with CF, with 
white patients more likely to be diagnosed with CF compared to those of other 
races. Male patients who resided in the Midwest U.S. region were also found to be 
at higher risk for a CF diagnosis.
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optimize spending on MS treatments and for clinical experts looking for improved 
understanding of the therapeutic benefits of natalizumab.
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objeCtives: This research was conducted to provide a systematic pairwise com-
parison of all available botulinum toxin type A treatments for cervical dystonia 
(CD) as there is a lack of direct head to head clinical trial data evidence. Three 
botulinum toxin type A products have been approved by the FDA for managing CD: 
AbobotulinumtoxinA, OnabotulinumtoxinA and IncobotulinumtoxinA. A pair-wise 
efficacy comparison was performed for all three toxins based on literature-reported 
clinical outcomes. Methods: Multi-armed randomized controlled trials (RCTs) for 
inclusion were identified using a systematic literature review. RCTs were assessed 
for comparability based on patient population and comparable efficacy outcome 
measures. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total 
score was selected as the efficacy outcome measurement for assessment. A mixed 
treatment comparison (MTC) was conducted using a Bayesian hierarchical model 
allowing indirect comparison of the efficacies of the interventions. Results: The 
network of six RCTs with fourteen arms formed a linear series of “steps” which 
facilitated the comparison of all botulinum toxin type A treatments of interest. 
Due to the limitation of available clinical data, this study only investigated the 
main effect of toxin treatments without explicitly considering potential confound-
ing factors such as gender and formulation differences. There was reasonable 
agreement between the number of unconstrained data points, residual deviance 
and pair-wise results, suggesting a coherent network. The results for TWSTRS 
total scale change from baseline for all treatments were: Placebo (mean -4.487, 
SE 1.402), AbobotulinumtoxinA (mean -11.08, SE 1.41), OnabotulinumtoxinA (mean 
-11.77, SE 1.44) and IncobotulinumtoxinA (mean -12.38, SE 1.79); where a negative 
number indicates symptom improvement. ConClusions: This research suggests 
that all botulinum toxin type A treatments were effective compared to placebo 
in cervical dystonia. However, based on this MTC analysis, there is no significant 
efficacy difference between AbobotulinumtoxinA, OnabotulinumtoxinA and 
IncobotulinumtoxinA.
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objeCtives: The understanding of the clinical meaningfulness of outcomes in 
schizophrenia is important to determine the value of new treatments for patients, 
caregivers, practitioners and payers. The aim of this research was to provide an 
overview of general concepts and methodologies applied to determine meaningful-
ness of endpoints, to describe how outcomes are measured in schizophrenia and 
how treatment success and clinical meaningfulness are defined in schizophrenia 
from a Health Technology Assessment (HTA) perspective. Methods: We conducted 
a targeted literature search focusing on antipsychotic treatment and clinical mean-
ingfulness of schizophrenia outcomes, a review of HTA submission guidelines, HTA 
reports in schizophrenia, a survey on individual country requirements in sixteen 
countries and an analogue analysis to identify payer definitions of clinical meaning-
ful differences. Results: No consistent approach exists from payers, or in the liter-
ature, to determine clinical meaningfulness in schizophrenia outcomes. Historically, 
payers have based their value assessments of antipsychotics on available clinical 
evidence using systematic literature reviews and meta-analyses. Most widely used 
efficacy endpoints in antipsychotic trials are changes in PANSS scores, BPRS and CGI 
(CGI-I and/or CGI-S). Payers noted considerable variation in the definition of clini-
cal meaningfulness to determine treatment response (20%-60% change in PANSS 
or BPRS score from baseline). Payers recommend validity should be demonstrated 
for clinical relevance of change on these endpoints using anchors such as patient-
reported, functional and global outcomes. Overall, payers suggest establishing a 
minimal clinically important difference (MCID) based on robust scientific criteria. 
Beyond the traditional clinical measures, payers would like to see complementary 
evidence on quality of life, patient satisfaction, family burden, resource utilization 
and hospitalization. ConClusions: Approaches to determine clinical meaningful-
ness in schizophrenia outcomes vary widely. Further research is needed to validate 
the meaningfulness of changes in commonly used clinical endpoints and generate 
additional payer relevant evidence on patient and caregiver burden.
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objeCtives: To examine the association between antidepressant drug use and C 
– Reactive Protein (CRP) among adults with inflammatory medical conditions after 
controlling for gender, race, age, income, Non-steroidal anti-inflammatory drug use, 
smoking, perceived health status, alcohol use and physical activity. Methods: 
Retrospective cross-sectional study with linked data from laboratory, prescription 
medication, medical conditions and demographic files of the National Health and 
Nutritional examination Survey (NHANES). The study sample (N = 3,492) consisted of 
adults (≥ 20 years) with any inflammatory condition (arthritis, gout, chronic obstruc-
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according to the AIT’s criteria could result in better clinical outcomes with little 
impact on the annual budget.
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objeCtives: To quantify the number and costs of relapses avoided over 2 
years in the first-line treatment of RRMS based on the findings of the Cochrane 
report. Methods: An Excel-based financial model estimated the relapses and costs 
incurred by a hypothetical cohort of 1000 RRMS patients treated with first-line 
disease-modifying drugs (DMDs). The modelled cohort evaluated the consequences 
of treatment with subcutaneous (SC) interferon beta-1a versus intramuscular 
(IM) interferon beta-1a, as this was the only comparison whose data quality was 
assessed as ‘high’ by the Cochrane Review (Filippini et al., 2013). Risk of relapse 
was based on the 2-year data from the Cochrane Review network meta-analysis. 
The analysis was performed from a US payer perspective. The cost of a relapse was 
sourced from Panitch et al., 2005, and adjusted to 2012 US dollars. Net annual cost 
of therapy was based on wholesale acquisition cost. Given the model’s short time 
horizon, disability-related costs were not included as these tend to be an important 
economic driver only over the long-term progression of the disease. In order to test 
how variability in the model’s inputs might impact the analysis’ results, two-way 
sensitivity analyses were performed based on the reported 95% risk of relapse cred-
ible intervals for SC interferon beta-1a and IM interferon beta-1a. Results: In a 
hypothetical cohort of 1000 RRMS patients, treatment with SC interferon beta-1a 
is expected to result in the avoidance of 173 (sensitivity analysis range: -20 to 399) 
relapses versus IM interferon beta-1a over 2 years. Assuming a direct cost of relapse 
of $5141, this represents a savings of $890,212 (sensitivity analysis range: -$102,138 
to $2,052,934) versus IM interferon beta-1a. ConClusions: Subcutaneous inter-
feron beta-1a is likely to result in fewer relapses and lower direct costs of relapse 
versus IM interferon beta-1a over a 2-year period treatment.
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For gaucher Disease iN the uNiteD states
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objeCtives: Gaucher disease (GD), a lysosomal storage disorder caused by muta-
tions in the gene encoding the enzyme glucocerebrosidase, requires life-long treat-
ment with enzyme replacement therapy (ERT). Currently available ERTs include 
imiglucerase, velaglucerase alfa, and taliglucerase alfa. Taliglucerase alfa is the first 
plant cell-expressed beta-glucocerebrosidase ERT approved for adults with type 
1 GD. The purpose of this analysis was to model the potential budget impact of 
taliglucerase alfa therapy for GD in the United States. Methods: A hypothetical 
budget impact model analysis was performed, based on total estimated number of 
GD patients treated, treatment costs, and estimated treatment distribution of each 
ERT. Costs in USD ($) per 200-unit vial were based on wholesale acquisition costs on 
ReadyPrice and Medi-Span databases. Annual costs were calculated using number 
of vials required. Actual cost savings may vary with factors beyond drug acquisition 
costs (eg, rebate programs) and may not reflect actual costs paid. Results: The 
estimated number of GD patients treated with ERT in the United States was 3,000. 
Drug costs for 200 units of ERT were: taliglucerase alfa–$595, velaglucerase alfa–$675, 
and imiglucerase–$793. Annual costs/patient were estimated at $328,440, $372,600, 
and $437,736 for taliglucerase alfa, velaglucerase alfa, and imiglucerase, respectively. 
Switching 50 patients to taliglucerase alfa, assuming same market share as national 
average, could save up to $4 million annually. The US health care system could 
save ~$100,000/patient annually if patients were switched to taliglucerase alfa. A 
20% increase in the number of patients receiving taliglucerase alfa could translate 
to an overall savings of ~$46 million annually. ConClusions: Taliglucerase alfa 
has the potential to provide a cost-saving alternative to other ERTs. This study was 
sponsored by Pfizer. Editorial support was provided by Peloton Advantage, LLC with 
funding from Pfizer.
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objeCtives: Souvenaid® is a medical food - an enriched nutritional formula - that 
contains specific nutrients reported to be deficient in patients with Alzheimer’s 
Disease (AD) and that are important in cognitive function, synapse formation and 
function. Clinical studies demonstrate that dietary management with Souvenaid® 
for 12 to 24 weeks results in a significant improvement in memory in patients with 
early AD. This study aims to estimate the budget impact of Souvenaid® for the 
dietary management of mild AD according to SUS perspective. Methods: An age 
related incidence of AD approach was used. Population size, according to different 
age categories, was derived from Brazilian statistics (IBGE) and combined to estimate 
the number of patients per age stratum. Average cost of AD was derived from a 
7-state Markov model developed to estimate the effect of Souvenaid® for mild AD 
versus no dietary management (NDM) of mild AD and combined with demographic 
data in each age stratum. Only direct costs, obtained from a public hospital in 
Brazil, were considered. The difference between Souvenaid® group and NDM was 
the 5-year budget impact estimated for SUS. Results: Considering a market pen-
etration of 10%, 13%, 15%, 17% and 20% each year, the estimated number of patients 
under Souvenaid® treatment is 11.002, 15.733, 19.969, 24.894 and 32.216, respectively, 
for years 1-5. Compared to NDM, the inclusion of Souvenaid® in the protocol of mild 
objeCtives: Triptan medication use is contraindicated in adults with migriane who 
have cardiovascular disease or cardiovascular (CV) risk factors (i.e., hypertension, 
diabetes, hyperlipidemia, and obesity). The objective of this study is to compare 
Triptan use among Migraineurs with and without cardiovascular disease (CVD) or 
CVD risk factors such as those with diabetes, hypertension, hyperlipidemia, and 
obesity. Methods: This is a retrospective cross-sectional study using data from 
2009 and 2011 Medical Expenditure Panel Survey (MEPS). The study sample con-
sisted of adults with migraine aged 22-64 years and alive during the calendar years 
(N = 1,142). Chi-square tests were used to compare rates of Triptan use among 
adults with and without CVD/CVD risk factors. Multiple logistic regressions were 
used to compare the likelihood of Triptan use among Migraineurs with and without 
CVD/CVD risk factors. All analyses accounted for the complex survey design of the 
MEPS. Results: Among adult Migraineurs, 26.3% with CVD/CVD risk and 34.3% 
without CVD reported Triptan medication use. After controlling for gender, age, 
race/ethnicity, marital status, education, employment, income level, insurance and 
medication coverage, perceived physical and mental health, current smoking and 
exercise, adults with CVD/CVD risk were less likely to use Triptans compared to 
adults without CVD/CVD risk. (Adjusted Odds Ratio: 0.59, 95% Confidence Interval 
[0.43-0.82]). ConClusions: Although adults with CVD/CVD risk were less likely 
to report Triptan use compared to adults without CVD/CVD risk, nearly 26% of 
Migraineurs with CVD/CVD risk reported Triptan use. The study findings suggest 
that Triptan medication use among adults with CVD/CVD risk is not consistent with 
recommended clinical guidelines.
Neurological DisorDers – cost studies
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objeCtives: To estimate the budget impact of adding delayed-release dimethyl 
fumarate, a new oral drug indicated for the treatment of relapsing forms of mul-
tiple sclerosis (MS) to a managed care formulary in the US. Methods: An Excel 
model was developed to compare the drug-related costs of the current mix of treat-
ments with the costs of an estimated treatment mix including delayed-release 
dimethyl fumarate for a managed care organization (MCO) with 1,000,000 covered 
lives. The number of people with relapsing forms of MS was estimated using pub-
lished prevalence data. Market share of delayed-release dimethyl fumarate was 
assumed to increase from 10% in 2013 to 25% in 2017 taken proportionately by 
market shares from all other DMTs. Drug costs included acquisition costs adjusted 
by patient payments and dispensing fees as well as administration, monitoring 
and adverse event costs. Annual relapse treatment costs were estimated using the 
relative risk reduction of a relapse for each DMT derived using a mixed-treatment 
comparison analysis. A one-way sensitivity analysis was performed. Results: 
The estimated budget impact of adding delayed-release dimethyl fumarate to 
the formulary was negative for the first 5 years: in 2014, with a market share of 
13.0%, the estimated budget decrease was 0.29% of the total annual costs for 
DMT-related and relapse treatment costs and a decrease of $0.011 per member 
per month (PMPM); in 2017, with a market share of 25.0%, the estimated budget 
decrease was 0.50% of the total annual costs and a decrease of $0.018 PMPM. 
Sensitivity analyses showed that the model was most sensitive to the acquisi-
tion costs of delayed-release dimethyl fumarate. ConClusions: Under model 
assumptions for market shares, adding delayed-release dimethyl fumarate to the 
MCO formulary would result in a small decrease in MCO costs for patients with 
relapsing forms of MS.
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objeCtives: In 2013, the Amyloid Imaging Taskforce (AIT) proposed that individuals 
with unexplained mild-cognitive impairment, possible AD, and early-onset demen-
tia are potentially appropriate for amyloid PET in the diagnosis of AD and other 
forms of dementia. This analysis quantified the budgetary impact of using amyloid 
PET according to the AIT’s criteria from the US payer perspective. Methods: An 
Excel-based model was developed for this analysis. The model projects the number 
of patients eligible for amyloid PET over a 3-year time horizon and calculates the 
incremental cost of using amyloid PET by considering direct medical resource uses 
for diagnostic work-up, dementia medications, and dementia care for patients stay-
ing in communities or institutions. Amyloid PET’s cost could be potentially offset by 
reducing diagnostic work-up time and resources use, unnecessary dementia treat-
ments and delaying disease progression and time to institutional care. The model 
was mainly populated with data from claims data analysis (Truven MarketScan® 
2007–2012) and a survey of 75 dementia practitioners in the US, supplemented 
with data from literature, public databases, and assumptions. All costs were esti-
mated in 2013 dollars. Results: Assuming an uptake of 5% incrementally each 
year, using amyloid PET increased the total cost by about $560,000 to $1,140,000 
per 1 million covered lives over 3 years (or $0.016 to $0.032 per member per month) 
when amyloid PET’s cost was set between $2,500 and $6,000 per scan. Amyloid PET’s 
cost was partially offset by reductions in diagnostic work-up time and resources 
use and costs of institutional care due to more timely and accurate diagnosis and 
treatment. These results were most sensitive to variations in the cost of amyloid 
PET and time horizon. ConClusions: Using amyloid PET in the diagnosis of AD 
